Dexmedetomidine upregulates microRNA-185 to suppress ovarian cancer growth via inhibiting the SOX9/Wnt/β-catenin signaling pathway

Dexmedetomidine (DEX) could serve as an adjuvant analgesic during cancer therapies. Abnormal expression of microRNAs (miRNAs) could lead to cancer development. This study was aimed to explore the roles of DEX in ovarian cancer (OC) development. OC cell lines SKOV3 and HO-8910 were treated with DEX,...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Cycle
Hlavní autoři: Tian, Hang, Hou, Lei, Xiong, Yumei, Cheng, Qiuju
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2021
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8098064/
https://ncbi.nlm.nih.gov/pubmed/33818283
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2021.1897270
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky